Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
9336 | 1165 | 46.5 | 89% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
27 | 3 | DEVELOPMENTAL BIOLOGY//DEVELOPMENT//AGR2 | 109777 |
1425 | 2 | WNT//BETA CATENIN//FRIZZLED | 7942 |
9336 | 1 | SCLEROSTIN//SOST//LRP5 | 1165 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | SCLEROSTIN | authKW | 3796702 | 20% | 61% | 238 |
2 | SOST | authKW | 1174952 | 5% | 73% | 61 |
3 | LRP5 | authKW | 562218 | 5% | 39% | 55 |
4 | SCLEROSTEOSIS | authKW | 462320 | 2% | 84% | 21 |
5 | SCLEROSTIN ANTIBODY | authKW | 455002 | 2% | 69% | 25 |
6 | ROMOSOZUMAB | authKW | 233114 | 1% | 68% | 13 |
7 | VAN BUCHEM DISEASE | authKW | 187201 | 1% | 71% | 10 |
8 | BLOSOZUMAB | authKW | 186373 | 1% | 89% | 8 |
9 | DKK1 | authKW | 176094 | 3% | 20% | 34 |
10 | HIGH BONE MASS | authKW | 170346 | 1% | 50% | 13 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Endocrinology & Metabolism | 11258 | 38% | 0% | 443 |
2 | Cell Biology | 1141 | 18% | 0% | 204 |
3 | Cell & Tissue Engineering | 625 | 2% | 0% | 26 |
4 | Developmental Biology | 372 | 4% | 0% | 46 |
5 | Biochemistry & Molecular Biology | 335 | 18% | 0% | 211 |
6 | Rheumatology | 212 | 3% | 0% | 32 |
7 | Genetics & Heredity | 153 | 6% | 0% | 72 |
8 | Dentistry, Oral Surgery & Medicine | 136 | 3% | 0% | 38 |
9 | Medicine, Research & Experimental | 121 | 5% | 0% | 58 |
10 | Orthopedics | 111 | 3% | 0% | 38 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | GENE FUNCT TARGET VALIDAT | 81899 | 0% | 63% | 5 |
2 | MUSCULOSKELETAL DIS AREA | 73192 | 1% | 31% | 9 |
3 | DIABET CLIN PEDIAT 2 | 52418 | 0% | 100% | 2 |
4 | EXPT ORTHOPAED KEF | 52418 | 0% | 100% | 2 |
5 | FUJI MEM MED SCI | 52418 | 0% | 100% | 2 |
6 | CELL SIGNALING CARCINOGENESIS | 50386 | 1% | 19% | 10 |
7 | ENDOCRINOLMETAB BONE DIS UNIT | 41930 | 0% | 40% | 4 |
8 | METAB DISORDERS | 39061 | 3% | 5% | 32 |
9 | ABS BIOMED SCI | 34944 | 0% | 67% | 2 |
10 | ENDOCRINOL RETICEF | 34944 | 0% | 67% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF BONE AND MINERAL RESEARCH | 52188 | 10% | 2% | 115 |
2 | BONE | 29831 | 7% | 1% | 87 |
3 | CURRENT OSTEOPOROSIS REPORTS | 5228 | 1% | 3% | 7 |
4 | BONE RESEARCH | 4228 | 0% | 4% | 4 |
5 | CALCIFIED TISSUE INTERNATIONAL | 3922 | 2% | 1% | 27 |
6 | OSTEOPOROSIS INTERNATIONAL | 3850 | 2% | 1% | 27 |
7 | JOURNAL OF CELLULAR BIOCHEMISTRY | 2265 | 2% | 0% | 28 |
8 | JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2178 | 4% | 0% | 45 |
9 | REVIEWS IN ENDOCRINE & METABOLIC DISORDERS | 1449 | 0% | 1% | 5 |
10 | JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS | 753 | 0% | 1% | 3 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | SCLEROSTIN | 3796702 | 20% | 61% | 238 | Search SCLEROSTIN | Search SCLEROSTIN |
2 | SOST | 1174952 | 5% | 73% | 61 | Search SOST | Search SOST |
3 | LRP5 | 562218 | 5% | 39% | 55 | Search LRP5 | Search LRP5 |
4 | SCLEROSTEOSIS | 462320 | 2% | 84% | 21 | Search SCLEROSTEOSIS | Search SCLEROSTEOSIS |
5 | SCLEROSTIN ANTIBODY | 455002 | 2% | 69% | 25 | Search SCLEROSTIN+ANTIBODY | Search SCLEROSTIN+ANTIBODY |
6 | ROMOSOZUMAB | 233114 | 1% | 68% | 13 | Search ROMOSOZUMAB | Search ROMOSOZUMAB |
7 | VAN BUCHEM DISEASE | 187201 | 1% | 71% | 10 | Search VAN+BUCHEM+DISEASE | Search VAN+BUCHEM+DISEASE |
8 | BLOSOZUMAB | 186373 | 1% | 89% | 8 | Search BLOSOZUMAB | Search BLOSOZUMAB |
9 | DKK1 | 176094 | 3% | 20% | 34 | Search DKK1 | Search DKK1 |
10 | HIGH BONE MASS | 170346 | 1% | 50% | 13 | Search HIGH+BONE+MASS | Search HIGH+BONE+MASS |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | BARON, R , KNEISSEL, M , (2013) WNT SIGNALING IN BONE HOMEOSTASIS AND DISEASE: FROM HUMAN MUTATIONS TO TREATMENTS.NATURE MEDICINE. VOL. 19. ISSUE 2. P. 179-192 | 119 | 54% | 356 |
2 | KE, HZ , RICHARDS, WG , LI, XD , OMINSKY, MS , (2012) SCLEROSTIN AND DICKKOPF-1 AS THERAPEUTIC TARGETS IN BONE DISEASES.ENDOCRINE REVIEWS. VOL. 33. ISSUE 5. P. 747 -783 | 106 | 50% | 107 |
3 | MONROE, DG , MCGEE-LAWRENCE, ME , OURSLER, MJ , WESTENDORF, JJ , (2012) UPDATE ON WNT SIGNALING IN BONE CELL BIOLOGY AND BONE DISEASE.GENE. VOL. 492. ISSUE 1. P. 1-18 | 107 | 40% | 152 |
4 | LERNER, UH , OHLSSON, C , (2015) THE WNT SYSTEM: BACKGROUND AND ITS ROLE IN BONE.JOURNAL OF INTERNAL MEDICINE. VOL. 277. ISSUE 6. P. 630 -649 | 75 | 66% | 8 |
5 | WEIVODA, MM , OURSLER, MJ , (2014) DEVELOPMENTS IN SCLEROSTIN BIOLOGY: REGULATION OF GENE EXPRESSION, MECHANISMS OF ACTION, AND PHYSIOLOGICAL FUNCTIONS.CURRENT OSTEOPOROSIS REPORTS. VOL. 12. ISSUE 1. P. 107 -114 | 60 | 91% | 7 |
6 | COSTA, AG , BILEZIKIAN, JP , LEWIECKI, EM , (2014) UPDATE ON ROMOSOZUMAB: A HUMANIZED MONOCLONAL ANTIBODY TO SCLEROSTIN.EXPERT OPINION ON BIOLOGICAL THERAPY. VOL. 14. ISSUE 5. P. 697 -707 | 55 | 93% | 9 |
7 | APPELMAN-DIJKSTRA, NM , PAPAPOULOS, SE , (2016) SCLEROSTIN INHIBITION IN THE MANAGEMENT OF OSTEOPOROSIS.CALCIFIED TISSUE INTERNATIONAL. VOL. 98. ISSUE 4. P. 370 -380 | 50 | 86% | 3 |
8 | ROSSINI, M , GATTI, D , ADAMI, S , (2013) INVOLVEMENT OF WNT/BETA-CATENIN SIGNALING IN THE TREATMENT OF OSTEOPOROSIS.CALCIFIED TISSUE INTERNATIONAL. VOL. 93. ISSUE 2. P. 121-132 | 62 | 70% | 45 |
9 | HONASOGE, M , RAO, AD , RAO, SD , (2014) SCLEROSTIN: RECENT ADVANCES AND CLINICAL IMPLICATIONS.CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY. VOL. 21. ISSUE 6. P. 437 -446 | 68 | 73% | 5 |
10 | WANG, YP , LI, YP , PAULSON, C , SHAO, JZ , ZHANG, XL , WU, MR , CHEN, W , (2014) WNT AND THE WNT SIGNALING PATHWAY IN BONE DEVELOPMENT AND DISEASE.FRONTIERS IN BIOSCIENCE-LANDMARK. VOL. 19. ISSUE . P. 379 -407 | 102 | 36% | 46 |
Classes with closest relation at Level 1 |